Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility-Reference-Cited by-同舟云学术

Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility

Published:2021-07-13 Issue:8 Volume:10 Page:804-825
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Musuamba Flora T.¹²³^ORCID,Skottheim Rusten Ine¹⁴^ORCID,Lesage Raphaëlle⁵⁶,Russo Giulia⁷,Bursi Roberta⁸,Emili Luca⁸,Wangorsch Gaby¹⁹,Manolis Efthymios¹¹⁰,Karlsson Kristin E.¹¹¹^ORCID,Kulesza Alexander¹²,Courcelles Eulalie¹²,Boissel Jean‐Pierre¹²,Rousseau Cécile F.¹³,Voisin Emmanuelle M.¹³^ORCID,Alessandrello Rossana¹⁴,Curado Nuno¹⁵,Dall’ara Enrico¹⁶,Rodriguez Blanca¹⁷^ORCID,Pappalardo Francesco⁷^ORCID,Geris Liesbet⁵⁶¹⁸

Affiliation:

1. EMA Modelling and Simulation Working Party Amsterdam The Netherlands

2. Federal Agency for Medicines and Health Products Brussels Belgium

3. Faculté des Sciences Pharmaceutiques Université de Lubumbashi Lubumbashi Congo

4. Norvegian Medicines Agency Oslo Norway

5. Biomechanics Section KU Leuven Leuven Belgium

6. Virtual Physiological Human Institute Leuven Belgium

7. Department of Drug and Health Sciences University of Catania Catania Italy

8. InSilicoTrials Technologies Milano Italy

9. Paul‐Ehrlich‐Institut (Federal Institute for Vaccines and Biomedicines) Langen Germany

10. European Medicines Agency Amsterdam The Netherlands

11. Swedish Medical Products Agency Uppsala Sweden

12. Novadiscovery Lyon France

13. Voisin Consulting Life Sciences Boulogne (Paris) France

14. AQuAS ‐ Agency for Health Quality and Assessment of Catalonia Catalonia Spain

15. Exploristics Belfast UK

16. Insigneo Institute Sheffield University Sheffield UK

17. Department of Computer Science British Heart Foundation Centre of Research Excellence University of Oxford Oxford UK

18. GIGA In silico Medicine Université de Liège Liège Belgium

Publisher

Wiley

Subject

Pharmacology (medical),Modelling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12669

Reference82 articles.

1. Commentary on the MID3 Good Practices Paper

2. In silico clinical trials: concepts and early adoptions

3. Model‐Informed Drug Development: Current US Regulatory Practice and Future Considerations

4. Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation

5. Physiologically based pharmacokinetic modeling in regulatory decision-making at the European Medicines Agency

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Artificial Intelligence and Anticancer Drug Development—Keep a Cool Head;Pharmaceutics;2024-01-31

2. Artificial Intelligence for Drug Discovery: Are We There Yet?;Annual Review of Pharmacology and Toxicology;2024-01-23

3. 3D inverse finite element modeling;Cartilage Tissue and Knee Joint Biomechanics;2024

4. In SilicoEvaluation of Cell Therapy in Acute versus Chronic Infarction: Role of Automaticity, Heterogeneity and Purkinje in Human;2023-12-12

5. Synthesis In Silico and ADMET Profile of Triazinethione Derivatives for Their Potential as Anti-Inflammatory Agents;Russian Journal of General Chemistry;2023-11